HMGB1 and non-small cell lung carcinoma: Although the results of the present study are noteworthy, there are some limitations of the study such as the retrospective character, the inclusion of larger (NSCLC) and smaller subgroups (SCLC), the classical chemotherapeutic treatment, the long storage time until HMGB1 measurement, and the use of a non-diagnostic immunoassay (RUO-test).